Update on the new classification of hepatic adenomas: Clinical, molecular, and pathologic characteristics

Archives of Pathology and Laboratory Medicine

Volumn 138, Issue 8, 2014, Pages 1090-1097

  Dhingra, Sadhna ^a   Fiel, M Isabel ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BIOLOGICAL MARKER; CTNNB1 PROTEIN, HUMAN; GLYCOPROTEIN GP 130; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HNF1A PROTEIN, HUMAN; IL6ST PROTEIN, HUMAN; TUMOR PROTEIN;

ADENOMA; DIFFERENTIAL DIAGNOSIS; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LARGE CORE NEEDLE BIOPSY; LIVER; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METABOLISM; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SEX RATIO;

ADENOMA; BETA CATENIN; BIOLOGICAL MARKERS; BIOPSY, LARGE-CORE NEEDLE; CARCINOMA, HEPATOCELLULAR; CYTOKINE RECEPTOR GP130; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER NEOPLASMS; MALE; MUTATION; NEOPLASM PROTEINS; PROGNOSIS; SEX DISTRIBUTION;

EID: 84907284181     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2013-0183-RA     Document Type: Review

References (58)

1. Barthelmes L, Tait IS. Liver cell adenoma and liver cell adenomatosis. HPB (Oxford). 2005;7(3): 186-196.
2. Rooks JB, Ory HW, Ishak KG, et al. Epidemiology of hepatic adenoma: the role of oral contraceptive use. JAMA 1979;242: 644-648.
3. Lin H, van den Esschert J, Liu C, van Gulik TM. Systematic review of hepatocellular adenoma in China and other regions. J Gastroenterol Hepatol. 2011; 26(1): 28-35.
4. Sasaki M, Nakanuma Y. Overview of hepatocellular adenoma in Japan [published online ahead of print September 2, 2012]. Int J Hepatol. 2012;2012: 648131. doi: 10.1155/2012/648131.
5. Greaves WO, Bhattacharya B. Hepatic adenomatosis. Arch Pathol Lab Med. 2008;132(12): 1951-1955.
6. Huurman VA, Schaapherder AF. Management of ruptured hepatic adenoma. Dig Surg. 2010;27(1): 56-60.
7. Farges O, Dokmak S. Malignant transformation of liver adenoma: an analysis of the literature. Dig Surg. 2010: 27(1): 32-38.
8. Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatic adenoma: new classification and relationship with HCC. Hepatology. 2006;43(3): 515-524.
9. Bioulac-Sage P, Laumonier H, Couchy G, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology. 2009;50(2): 481-489.
10. Bioulac-Sage P, Rebouissou S, Sa Cunha A, et al. Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. Gastroenterology. 2005;128(5): 1211-1218.
11. Baum JK, Bookstein JJ, Holtz F, Klein EW. Possible association between benign hepatomas and oral contraceptives. Lancet. 1973;2(7835): 926-929.
12. Heinemann LA, Weimann A, Gerken G, Thiel C, Schlaud M, DoMinh T. Modern oral contraceptive use and benign liver tumors: the German Benign Liver Tumor Case-Control study. Eur J Contracept Reprod Health Care. 1998;3(4): 194-200.
13. Steinbrecher UP, Lisbona R, Huang SN, Mishkin S. Complete regression of hepatic adenoma after withdrawal of oral contraceptives. Dig Dis Sci. 1981; 26(11): 1045-1051.
14. Soe KL, Se M, Gluud C. Liver pathology associated with the use of anabolic-androgenic steroids. Liver. 1992;12(2): 73-79.
15. Granǵe JD,Gúechot J, Legendre C, Giboudeau J, Darnis F, Poupon R. Liver adenoma and focal nodular hyperplasia in a man with high endogenous sex steroids. Gastroenterology. 1987;93(6): 1409-1413.
16. Velazquez I, Alter BP. Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions. Am J Hematol. 2004;77(3): 257-267.
17. Bannasch P. Hepatocellular glycogenosis and hepatic neoplasms. Toxicol Pathol. 2010;38(6): 1000-1002.
18. Beuers U, Richter WO, Ritter MM, Wiebecke B, Schwandt P. Klinefelter's syndrome and liver adenoma. J Clin Gastroenterol. 1991;13(2): 214-216.
19. Toiyama Y, Inoue Y, Yasuda H, et al. Hepatocellular adenoma containing hepatocellular carcinoma in a male patient with familial adenomatous polyposis coli: report of a case. Surg Today. 2011;41(10): 1442-1446.
20. Bunchorntavakul C, Bahirwani R, Drazek D, et al. Clinical features and natural history of hepatocellular adenomas: the impact of obesity. Aliment Pharmacol Ther. 2011;34(6): 664-674.
21. Bioulac-Sage P, Taouji S, Possenti L, Balabaud C. Hepatocellular adenoma subtypes: the impact of overweight and obesity. Liver Int. 2012;32(8): 1217-1221.
22. Chavez PR, Lian F, Chung J, et al. Long-term ethanol consumption promotes hepatic tumorigenesis but impairs normal hepatocyte proliferation in rats. J Nutr. 2011;141(6): 1049-1055.
23. Sakellariou S, Al-Hussaini H, Scalori A, et al. Hepatocellular adenoma in glycogen storage disorder type 1: a clinicopathological and molecular study. Histopathology. 2012;60(6B): E58-E65. doi: 10.1111/j.1365-2559.2011.04153.x.
24. Maylee H, Harada K, Igarashi S, et al. Case of telangiectatic/ inflammatory hepatocellular adenoma arising in a patient with primary sclerosing cholangitis. Hepatol Res. 2012;42(6): 611-618.
25. Sasaki M, Yoneda N, Kitamura S, Sato Y, Nakanuma Y. A serum amyloid A-positive hepatocellular neoplasm arising in alcoholic cirrhosis: a previously unrecognized type of inflammatory hepatocellular tumor. Mod Pathol. 2012; 25(12): 1584-1593.
26. Seo JM, Lee SJ, Kim SH, Park CK, Ha SY. Hepatocellular carcinoma arising from hepatocellular adenoma in a hepatitis B virus-associated cirrhotic liver. Clin Radiol. 2012;67(4): 329-333.
27. Bluteau O, Jeannot E, Bioulac-Sage P, et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet. 2002;32(2): 312-315.
28. Chen YW, Jeng YM, Yeh SH, Chen PJ. p53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. Hepatology. 2002;36(4, pt 1): 927-935.
29. Rebouissou S, Amessou M, Couchy G, et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature. 2009; 457(7226): 200-204.
30. Rebouissou S, Imbeaud S, Balabaud C, et al. HNF1 alpha inactivation promotes lipogenesis in human hepatic adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation. J Biol Chem. 2007;282(19): 14437-14446.
31. Jeannot E, Poussin K, Chiche L, et al. Association of CYP1B1 germ line mutations with hepatocyte nuclear factor 1a-mutated hepatic adenoma. Cancer Res. 2007;67(6): 2611-2616.
32. Bacq Y, Jacquemin E, Balabaud C, et al. Familial liver adenomatosis associated with hepatocyte nuclear factor-1a inactivation. Gastroenterology 2003;125(5): 1470-1475.
33. Rebouissou S, Bioulac-Sage P, Zucman-Rossi J. Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol. 2008;48(1): 163-170.
34. Chen PJ. Genetic mutation in hepatic adenoma: seeing is believing. J Hepatol. 2006;45(6): 767-769.
35. Bioulac-Sage P, Balabaud C, Zucman-Rossi J. Subtype classification of hepatic adenoma. Dig Surg. 2010;27(1): 39-45.
36. Paradis V, Benzekri A, Dargère D, et al. Telangiectatic focal nodular hyperplasia: a variant of hepatic adenoma. Gastroenterology. 2004;126 (5): 1323-1329.
37. Flejou JF, Barge J, Menu Y, et al. Liver adenomatosis: an entity distinct from liver adenoma? Gastroenterology. 1985;89(5): 1132-1138.
38. Stoot JH, Coelen RJ, De Jong MC, Dejong CHC. Malignant transformation of hepatic adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB (Oxford). 2010;12(8): 509-522
39. Hechtman JF, Raoufi M, Fiel MI, et al. Hepatocellular carcinoma arising in a pigmented telangiectatic adenoma with nuclear b-catenin and glutamine synthetase positivity: case report and review of the literature. Am J Surg Pathol. 2011;35(6): 927-932.
40. Bioulac-Sage P, Cubel G, Balabaud C, et al. Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers. Semin Liver Dis. 2011;31(1): 91-103.
41. Bioulac-Sage P, Laumonier H, Balabaud CP. Benign hepatocellular tumors. In: Saxena R eds. Practical Hepatic Pathology: A Diagnostic Approach. 1st ed. Philadelphia, PA: Elsevier Saunders; 2011: 473-488. Pattern Recognition Series; vol 2.
42. Paradis V, Laurent A, Flejou JF, Vidaud M, Bedossa P. Evidence for the polyclonal nature of focal nodular hyperplasia of the liver by the study of Xchromosome inactivation. Hepatology. 1997;26(4): 891-895.
43. Paradis V, Champault A, Ronot M, et al. Telangiectatic adenoma: an entity associated with increased body mass index and inflammation. Hepatology. 2007; 46(1): 140-146.
44. Bioulac-Sage P, Balabaud C, Wanless I. Focal nodular hyperplasia and hepatocellular adenoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon, France: IARC Press; 2010: 198-204. World Health Organization Classification of Tumours; vol 3.
45. Bioulac-Sage P, Cubel G, Taouji S, et al. Immunohistochemical markers on needle biopsies are helpful for the diagnosis of focal nodular hyperplasia and hepatocellular adenoma subtypes. Am J Surg Pathol. 2012;36(11): 1691-1699.
46. Shafizadeh N, Kakar S. Diagnosis of well-differentiated hepatocellular lesions: role of immunohistochemistry and other ancillary techniques. Adv Anat Pathol. 2011;18(6): 438-445.
47. Lagana SM, Salomao M, Bao F, Moreira RK, Lefkowitch JH, Remotti HE. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma. Appl Immunohistochem Mol Morphol. 2013;21(2): 170-176.
48. Evason KJ, Grenert JP, Ferrell LD, Kakar S. Atypical hepatocellular adenoma-like neoplasms with b-catenin activation show cytogenetic alterations similar to well-differentiated hepatocellular carcinomas. Hum Pathol. 2013; 44(5): 750-758.
49. Laumonier H, Bioulac-Sage P, Laurent C, Zucman-Rossi J, Balabaud C, Trillaud H. Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology. 2008;48(3): 808-818.
50. Buell JF, Tranchart H, Cannon R, Dagher I. Management of benign hepatic tumors. Surg Clin North Am. 2010;90(4): 719-735.
51. Grazioli L, Federle MP, Brancatelli G, Ichikawa T, Olivetti L, Blachar A. Hepatic adenomas: imaging and pathologic findings. Radiographics. 2001;21(4): 877-892.
52. Shanbhogue A, Shah SN, Zaheer A, Prasad SR, Takahashi N, Vikram R. Hepatic adenomas: current update on genetics, taxonomy, and management. J Comput Assist Tomogr. 2011;35(2): 159-166.
53. Assy N, Nasser G, Jibre AD, Beniashvili J, Elias S, Zidan J. Characteristics of common solid liver lesions and recommendations for diagnostic workup. World J Gastroenterol. 2009;15(26): 3217-3227.
54. Gordon SC, Reddy KR, Livingstone AS, Jeffers LJ, Schiff ER. Resolution of a contraceptive-steroid-induced hepatic adenoma with subsequent evolution into hepatocellular carcinoma. Ann Intern Med. 1986;105(4): 547-549.
55. Farges O, Ferreira N, Dokmak S, Belghiti J, Bedossa P, Paradis V. Changing trends in malignant transformation of hepatocellular adenoma. Gut. 2011;60(1): 85-89.
56. van Aalten SM, Witjes CD, de Man RA, Ijermans JN, Terkivatan T. Can a decision-making model be justified in the management of hepatocellular adenoma. Liver Int. 2012;32(1): 28-37.
57. Dokmak S, Paradis V, Vilgrain V, et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology. 2009;137(5): 1698-1705.
58. Deneve JL, Pawlik TM, Cunningham S, et al. Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy. Ann Surg Oncol. 2009;16(3): 640-648.